CIM Stock Analysis: Chimera Investment | NYSE
REIT - Mortgage | NYSE, USA | Market Cap: 1.100m USD | 12M Return: 6.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.67M
EPS Trend: 20.6%
Qual. Beats: 0
Rev. Trend: 87.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Chimera Investment Corporation (NYSE: CIM) is a U.S.-based real estate investment trust (REIT) that operates through two segments: Investment Portfolio and Residential Origination. The company invests in, originates, and manages a diversified range of mortgage assets, including residential mortgage loans, agency and non-agency mortgage-backed securities (MBS), business purpose and investor loans, mortgage servicing rights, and other real estate-related assets. It also invests across investment grade, non-investment grade, and non-rated securities, and offers third-party advisory services.
As a Mortgage REIT, Chimera is required by federal tax rules to distribute at least 90% of its taxable income as dividends to shareholders. Incorporated in 2007 and headquartered in New York, the company leverages subsidiaries to manage its portfolio and generate returns primarily from the spread between the yield on its mortgage assets and its cost of funding.
- Agency MBS spreads tighten boosting portfolio net interest income
- Book value pressured by mortgage credit spread widening
- Origination volumes fall as mortgage rates climb higher
| Net Income: 19.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -1.83 > 1.0 |
| NWC/Revenue: -1.12k% < 20% (prev 2.59k%; Δ -3.71k% < -1%) |
| CFO/TA -0.00 > 3% & CFO -54.4m > Net Income 19.3m |
| Net Debt (12.3b) to EBITDA (323.6m): 37.88 < 3 |
| Current Ratio: 0.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.7m) vs 12m ago 1.54% < -2% |
| Gross Margin: 50.13% > 18% (prev 65.87%; Δ -15.74% > 0.5%) |
| Asset Turnover: 4.36% > 50% (prev 3.26%; Δ 1.10% > 0%) |
| Interest Coverage Ratio: 0.53 > 6 (EBIT TTM 307.2m / Interest Expense TTM 577.8m) |
| A: -0.44 (Total Current Assets 592.4m - Total Current Liabilities 7.69b) / Total Assets 16.0b |
| B: -0.13 (Retained Earnings -2.11b / Total Assets 16.0b) |
| C: 0.02 (EBIT TTM 307.2m / Avg Total Assets 14.6b) |
| D: 0.18 (Book Value of Equity 2.46b / Total Liabilities 13.5b) |
| Altman-Z'' = -3.01 = D |
As of July 13, 2026, the stock is trading at USD 13.13 with a total of 346,462 shares traded. Over the past week, the price has changed by +0.08%, over one month by +1.62%, over three months by +1.09% and over the past year by +6.46%.
Current recommended Stop Loss: 12.70 (which is 3.3% or 1.5 ATR below the current price).
Chimera Investment has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold CIM.
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 12.9% |
P/E Forward = 6.4309
P/S = 5.1184
P/B = 0.4455
P/EG = 3.3319
Revenue TTM = 635.9m USD
EBIT TTM = 307.2m USD
EBITDA TTM = 323.6m USD
Long Term Debt = 12.7b USD (from longTermDebt, last quarter)
Short Term Debt = 7.69b USD (from shortTermDebt, last quarter)
Debt = 12.7b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.3b USD (calculated: Debt 12.7b - CCE 476.2m)
Enterprise Value = 13.4b USD (1.10b + Debt 12.7b - CCE 476.2m)
Interest Coverage Ratio = 0.53 (Ebit TTM 307.2m / Interest Expense TTM 577.8m)
EV/FCF = -245.7x (Enterprise Value 13.4b / FCF TTM -54.4m)
FCF Yield = -0.41% (FCF TTM -54.4m / Enterprise Value 13.4b)
FCF Margin = -8.55% (FCF TTM -54.4m / Revenue TTM 635.9m)
Net Margin = 3.03% (Net Income TTM 19.3m / Revenue TTM 635.9m)
Gross Margin = 50.13% ((Revenue TTM 635.9m - Cost of Revenue TTM 317.1m) / Revenue TTM)
Gross Margin QoQ = 22.00% (prev 92.99%)
Tobins Q-Ratio = 0.84 (Enterprise Value 13.4b / Total Assets 16.0b)
Interest Expense / Debt = 4.54% (Interest Expense 577.8m / Debt 12.7b)
Taxrate = 0.97% (2.27m / 232.8m)
NOPAT = 304.2m (EBIT 307.2m * (1 - 0.97%))
Current Ratio = 0.08 (Total Current Assets 592.4m / Total Current Liabilities 7.69b)
Debt / Equity = 5.17 (Debt 12.7b / totalStockholderEquity, last quarter 2.46b)
Debt / EBITDA = 37.88 (Net Debt 12.3b / EBITDA 323.6m)
Debt / FCF = -225.5 (out of range, set to none) (Net Debt 12.3b / FCF TTM -54.4m)
Total Stockholder Equity = 2.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.13% (Net Income 19.3m / Total Assets 16.0b)
RoE = 0.75% (Net Income TTM 19.3m / Total Stockholder Equity 2.56b)
RoCE = 2.01% (EBIT 307.2m / Capital Employed (Equity 2.56b + L.T.Debt 12.7b))
RoIC = 1.91% (NOPAT 304.2m / Invested Capital 15.9b)
WACC = 4.82% (E(1.10b)/V(13.8b) * Re(8.63%) + D(12.7b)/V(13.8b) * Rd(4.54%) * (1-Tc(0.01)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 3.44%
[DCF] Fair Price = unknown (Cash Flow -54.4m)
EPS Correlation: 20.61 | EPS CAGR: 2.07% | SUE: 0.56 | # QB: 0
Revenue Correlation: 87.47 | Revenue CAGR: 69.83% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.53 | Chg30d=+5.50% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.53 | Chg30d=-0.47% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=2.12 | Chg30d=+2.42% | Revisions=-25% | GrowthEPS=+26.2% | GrowthRev=+22.2%
EPS next Year (2027-12-31): EPS=2.19 | Chg30d=+0.46% | Revisions=-25% | GrowthEPS=+3.1% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -22% (up=2, down=4)